An observational study in Systemic Lupus Erythematosus, sponsored by Region Stockholm. Recruiting at 1 site in Sweden. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-08-03.
Sponsored by Region Stockholm · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Lupus Erythematosus, Systemic with a site in Sweden — 6 open to participants now, 10 under way, 2 of them phase 3. Lupus Erythematosus, Systemic · Sweden.
Among the 19 studies in Lupus Erythematosus, Systemic with a site in Sweden, this one is the only one that started in 2015, is one of 6 observational ones, and was the 18th registered.
1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →6 of the 19 studies in Lupus Erythematosus, Systemic with a site in Sweden are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Sweden
Women only
Bristol-Myers Squibb · Sites in Sweden, United States, Argentina and 10 more countries
Ages 16+
Fate Therapeutics · Sites in Sweden, United States, France and 1 more country
Ages 12–70
Karolinska Institutet · Sites in Sweden
Ages 18+
Karolinska Institutet · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 7
First in 2006; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 900 is above the median of 151 across 281 observational studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 275 across the 13 interventional studies, 396 across the 6 observational. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 19 have an industry lead sponsor. The 10 most frequent:
Region Stockholm is the lead sponsor of 122 studies on the registry; 70 are open to participants now.
Region Stockholm has 1 study filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
1 of the studies in Lupus Erythematosus, Systemic with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06308978Fate TherapeuticsA Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Lupus Erythematosus, Systemic with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to investigate different phenotypes among patients with SLE and to compare with matched general population controls. The main questions we aim to answer are:
A To investigate if subgroups of patients with systemic lupus erythematosus (SLE) defined by autoantibodies, genetic predisposition or biomarkers, rather than the present diagnostic entities account for the high risk of premature vascular disease.
B To perform in depth studies of selected patient groups to shed light on the autoimmune mechanisms behind antiphospholipid (aPL) antibodies and nephritis and their association to vascular disease in SLE and APS Participants will be investigated in person by a nurse and a rheumatologist. Data on previous and present disease characteristics, anthropometric measurements and health related quality of life (according to selfreported questionnaires) will be entered into a data base. Blood samples (plasma serum and DNA), urine and saliva is stored in a corresponding biobank.
Researchers will compare identified subgroups of SLE patients to each other and to matched population controls.
The clinical base for this application is a series of cross-sectional studies, performed every 10 years, including all consenting SLE patients at Rheumatology Karolinska. The first studies were initiated 1995-99, with second follow-up 2004-14. Since 2015, a third follow-up of prevalent and new cases is ongoing (presently comprising 400 patients, inclusions have been temporarily slowed by the Covid-19 pandemic). Very detailed clinical characterization, lifestyle questionnaires, together with results from carotid ultrasound and bone mineral density measures have been tabulated. General disease activity as well as features of lupus nephritis, and detailed autoantibody profiles are recorded at inclusion. Samples (plasma, serum, DNA, urine and saliva) are stored. We have a common database for the three cross-sectional studies. The total number of well-characterized SLE patients in these studies is today 867 SLE patients and >250 APS patients.
Population based controls identified in the national population registry (NPR), individually matched for age, sex, and residency have been investigated in person according to the same structured protocol (n=320). New controls will be included to match the "2015+ study".
SLE patients as described above who are cared for at karolinska University Hospital, Danderyds Hospital or Center forRheumathology (CFR) in Stockholm and matched general population controls
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
SLE according to criteria (ACR82 or SLICC 2012) and consenting to participate
Exclusion Criteria:
Not possible to read and understand patient information due to language barriers or psychological/psychiatric disorders Not consenting
-
Patients fulfilling ACR 1982 or SLICC 2012 criteria for SLE. No interventions
General population controls matched from the National Patient Registries for age, gender and area of living
Autoantibody defined subgroups
Subgroups will be defined based on presence of autoantibodies
Time frame: 2024- 2027
Cardiovascular events
Cardiovascular events will be collected during follow up in National Patient Registries
Time frame: 2024-2027
Plan to share: Yes — Clinical and autoantibody data collected at inclusion
Supporting information: Study protocol, Informed consent form, Clinical study report
Time frame: July 15 2025 until July 15 2027
Access criteria: Selected data will be shared with Christian Lood, University of Washington USA, using Managed File Transfer at Karolinska Institutet.
No publications or documents are linked to this record.
Started Feb 2015 (actual). Primary completion is estimated for Dec 2029, 178 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupus Erythematosus, Systemic →